ArticleAmerican journal of cancer research2025
Cost-effectiveness analysis of trilaciclib for preventing myelosuppression in small cell lung cancer patients treated with etoposide, carboplatin, and atezolizumab.
Xiaoya Hu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.